Mark Klinger

Company: Adaptive Biotechnologies

Job title: Vice President, Cellular Research & Innovation

Seminars:

Disease-Specific TCR Clusters Inform Novel Target Discovery & Therapeutics in Autoimmunity 11:10 am

Overview of Adaptive's immune medicine drug discovery platform to identify naturally occuring, antigen-specific T cell receptors (TCRs) Selection and characterization of antigen-specific TCR candidates to inform the development of immune-based therapies Read more

day: Conference Day One